Generic Elidel Availability
ELIDEL (pimecrolimus - cream;topical)
Manufacturer: VALEANT BERMUDA
Approval date: December 13, 2001
Strength(s): 1% [RLD]
Has a generic version of Elidel been approved?
No. There is currently no therapeutically equivalent version of Elidel available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elidel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Heteroatoms-containing tricyclic compounds
Issued: June 15, 1999
Inventor(s): Baumann; Karl & Emmer; Gerhard
Assignee(s): Novartis AG
The invention concerns the compounds of formula I ##STR1## wherein the substituents have various significances. They are prepared by several processes including epimerizing replacement, treatment with cyanogen bromide or thiophosgene, treatment with an acid having a non-nucleophilic anion, treatment with dimethylsulfoxide and acetic anhydride, acylation, treatment with an oxalyl derivative and ammonia, methylation, oxidation, deprotection and protection. They possess interesting pharmacological activity as antiinflammatory, immunosuppressant, antiproliferative and chemotherapeutic drug resistance reversing agents.Patent expiration dates:
- December 15, 2016✓
- December 15, 2016
Crystalline macrolides and process for their preparation
Issued: July 23, 2002
Inventor(s): Cornelia; Dosenbach & Maximilian; Grassberger & Otto; Hartmann & Amarylla; Horvath & Jean-Paul; Mutz & Gerhard; Penn & Sabine; Pfeffer & Dierk; Wieckhusen
Assignee(s): Novartis AG
33-Epichloro-33-desoxyascomycin of formula I and various tautomeric or forms thereof, in crystalline form, such as Form A and Form B. Their preparation involves appropriately converting amorphous compound of formula I, or compound of formula I in other than Form A, or compound of formula I in other than Form B, respectively, from a solution thereof under crystallization-inducing conditions or conditions inducing preferential crystallization of Form A or B, respectively. Such crystals are particularly indicated for use in the preparation of topical galenical forms of the compound for pharmaceutical use, e.g. creams, emulsions and ointments.Patent expiration dates:
- June 26, 2018
- December 26, 2018✓
- June 26, 2018
More about Elidel (pimecrolimus topical)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 25 Reviews – Add your own review/rating
- Drug class: miscellaneous topical agents
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|